Naomi Falk, MD
Retina Specialist · Slingerlands, NYNPI 1649271859
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Amgen at 30.1% of the total. 2025 is the largest year on record at $135, 7.0 times the $19 reported in 2020. That places this record below the midpoint for retina specialist clinicians in NY, where the typical reported total is $2,298.
Across 13 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$85
- AbbVie$76
- Harrow Eye, LLC$45
- Alimera Sciences, Inc.$34
- Apellis Pharmaceuticals, Inc.$22
- Carl Zeiss Meditec AG$19
Across 89 payments — averaging $4892.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$426K
- Eyepoint US, Inc.$6K
- Janssen Research & Development, LLC$4K
What the payments were for
- Food & beverage$26293%
- Gifts$197%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $85 |
| AbbVie | 3 | $76 |
| Harrow Eye, LLC | 2 | $45 |
| Alimera Sciences, Inc. | 2 | $34 |
| Apellis Pharmaceuticals, Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
How this compares
$281 in reported general payments places this provider in the 10th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 252 | $47,628 |
| ProlensaBromfenac Sodium | 31 | $13,124 |
| Prednisolone Acetate | 179 | $11,425 |
| Difluprednate | 52 | $5,827 |
| IlevroNepafenac | 12 | $4,859 |
| Ketorolac Tromethamine | 96 | $3,127 |
| Brimonidine Tartrate | 54 | $2,997 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 66 | $1,533 |
| Atropine Sulfate | 19 | $1,255 |
| Acetazolamide ErAcetazolamide | 19 | $1,019 |
| Dorzolamide Hcl | 51 | $895 |
| ValacyclovirValacyclovir Hcl | 15 | $809 |
| Ofloxacin | 34 | $728 |
| Timolol Maleate | 57 | $679 |
| Latanoprost | 29 | $407 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Slingerlands
- Spencer LangevinSlingerlands$2K
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Avnish DeobhaktaBrooklyn$46K
- Edward HallRochester$38K
- Philip NilesWilliamsville$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.